AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

ApoE Treatment for Osteogenesis Imperfecta

Detailed Technology Description: Clinicians at Nationwide Children's Hospital have found that Apolipoprotein E can be used as a treatment for Osteogenesis Imperfecta without the issues related to mesenchymal stem/stromal cell therapy.

Countries: Not Available

Application No.: None

*Abstract: Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break from little to no apparent cause. Mesenchymal stem/stromal cell (MSC) therapy has been found to effectively treat bone growth impairment in OI, but these treatments are not consistently effective and have safety concerns. Clinicians at Nationwide Children's Hospital have found that MSC treatment induces release of Apolipoprotein E (ApoE) into the serum, which then stimulates chondrocyte proliferation in the growth plate. This demonstrates that ApoE can be used as a treatment for OI, without the issues related to MSC therapy.

*Inquiry: Andrew CorrisThe Research Institute at Nationwide Children’s HospitalOffice of Technology Commercialization700 Children’s DriveColumbus, OH 43205T: (614) 355-1604 F: (614) 722-2716Andrew.Corris@nationdwidechildrens.org

*IP Issue Date: None

*IP Type: Other Patent

Country/Region: USA

For more information, please click Here